GRDNHealthcare · Medical Care FacilitiesThe 7 Wall Street analysts covering Guardian Pharmacy Services, Inc. hold a median 12-month price target of $50 — +18.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 3 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Guardian Pharmacy Services, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (92): Analysts have, on balance, been raising their forecasts.
Value (29): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on GRDN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +18.8% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2026 | Keybanc | Initiates | Overweight | $52 |
| 21 Sept 2026 | Truist Securities | Maintains | Buy | $47 → $51 |
| 7 Aug 2026 | Oppenheimer | Maintains | Outperform | $43 → $49 |
| 7 Aug 2026 | Oppenheimer | Maintains | Outperform | — |
| 17 June 2026 | B of A Securities | Maintains | Buy | — |
| 17 June 2026 | B of A Securities | Maintains | Buy | $42 → $47 |
| 17 June 2026 | Truist Securities | Maintains | Buy | $43 → $47 |
| 17 June 2026 | Truist Securities | Maintains | Buy | — |
| 7 May 2026 | Oppenheimer | Maintains | Outperform | — |
| 27 Apr 2026 | B of A Securities | Initiates | Buy | — |
| 13 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 30 Mar 2026 | Jefferies | Initiates | Buy | — |
| 12 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 12 Mar 2026 | Truist Securities | Maintains | Buy | — |
| 14 Jan 2026 | Stephens & Co. | Maintains | Overweight | — |
| 14 Nov 2025 | Truist Securities | Maintains | Buy | — |
| 10 Oct 2025 | Oppenheimer | Initiates | Outperform | — |
| 26 Sept 2025 | Truist Securities | Maintains | Buy | — |
| 19 May 2025 | Truist Securities | Reiterates | Buy | — |
| 11 Apr 2025 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
GRDN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Guardian Pharmacy Services, Inc. returned +47.7% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 19% of US stocks
Cheaper than 55% of US stocks
Cheaper than 8% of US stocks
Cheaper than 12% of US stocks
Higher than 33% of US stocks
Higher than 87% of US stocks
Higher than 24% of US stocks
Higher than 51% of US stocks
Higher than 58% of US stocks
Higher than 88% of US stocks
Higher than 96% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Guardian Pharmacy Services, Inc. has a market value of $2.7B and an enterprise value of $2.6B.
Revenue in the twelve months to 30 June 2026: $1.5B. The latest quarter grew 2.2% year on year.
Net income over the same four quarters: $66.5M, a 4.5% net margin.
Diluted earnings per share, trailing twelve months: $1.03.
Free cash flow in the twelve months to 30 June 2026: $79.8M.
Guardian Pharmacy Services, Inc. spent $30.3M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 40.9×; forward P/E: 29.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Guardian Pharmacy Services, Inc. employs 3,600 people — $407K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Guardian Pharmacy Services, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Guardian Pharmacy Services acquired Van's Institutional Pharmacy, a long-term care pharmacy based in Martin, Tennessee. The headline says the acquisition expands Guardian's footprint in Tennessee and Kentucky.
Why it matters — GRDN watchers may note the acquisition as an expansion of the company's pharmacy footprint in two states.
Guardian Pharmacy Services announced it will attend the Stephens Investment Conference in Nashville on November 18, 2026. CEO Fred Burke will participate in a fireside chat at 9:30 a.m. Central, with a live audio webcast available to the public.
Why it matters — GRDN watchers may follow the conference appearance for company updates and management commentary.
Guardian Pharmacy Services said it will release third-quarter 2026 financial results after market close on November 5, 2026. Management will discuss the results on a conference call at 4:30 p.m. Eastern Time, available by webcast or phone.
Why it matters — GRDN watchers can note when the company plans to report results and how to access management’s discussion.
Zacks Investment Research highlights Guardian Pharmacy Services, Inc. (GRDN) among five top stock picks identified using DuPont analysis rather than simple return-on-equity calculations. The other featured stocks are CNXN, ECG, EXPD and PBF.
Why it matters — A GRDN watcher would care because the stock is being singled out in an analyst screen as one of five top picks, signaling favorable attention from Zacks Investment Research.
Guardian Pharmacy Services, Inc. (NYSE: GRDN) has announced the acquisition of assets from Nautilus Pharmacy, a Tennessee-based pharmacy business. The announcement was made via Business Wire.
Why it matters — This acquisition expands Guardian Pharmacy Services' operations and market presence in Tennessee.
The 7 Wall Street analysts covering Guardian Pharmacy Services, Inc. have a median 12-month price target of $50, with estimates ranging from $47 to $52. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Guardian Pharmacy Services, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Guardian Pharmacy Services, Inc. 77 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Guardian Pharmacy Services, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +18.8% from the last close, and Ticker Nerd's factor model ranks Guardian Pharmacy Services, Inc. 77 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Guardian Pharmacy Services, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GRDN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $47 to $52 over the next 12 months.
Guardian Pharmacy Services, Inc. returned +47.7% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Guardian Pharmacy Services, Inc. Class A Common Stock is the equity security of Guardian Pharmacy Services, a U.S.-based long-term care pharmacy services company headquartered in Atlanta, Georgia.
The most recent item we track (Business Wire, 2 Nov 2026): "Guardian Pharmacy Services Acquires Van's Institutional Pharmacy, Expanding Footprint in Tennessee and Kentucky". Guardian Pharmacy Services acquired Van's Institutional Pharmacy, a long-term care pharmacy based in Martin, Tennessee. The headline says the acquisition expands Guardian's footprint in Tennessee and Kentucky.
Guardian Pharmacy Services, Inc. Class A Common Stock is the equity security of Guardian Pharmacy Services, a U.S.-based long-term care pharmacy services company headquartered in Atlanta, Georgia. The company provides technology-enabled pharmacy solutions for residents of long-term care facilities, including assisted living facilities, behavioral health facilities, group homes, skilled nursing communities, and organizations serving individuals with intellectual and developmental disabilities. Its services combine clinical support, medication dispensing, and administration capabilities designed to help care teams manage complex medication regimens in lower-acuity settings. Guardian Pharmacy Services also offers data-driven tools and operational support that help local pharmacies coordinate workflows, monitor prescriptions, and improve service delivery across care communities. The Class A Common Stock represents ownership in a business focused on pharmacy services within the healthcare sector, supporting the infrastructure that connects medication management with resident care in long-term care environments.
CEO Mr. Fred P. Burke · 3,600 employees · United States · https://guardianpharmacy.com
